Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 167 | uM | 7495.074 | 0.0023 | -0.9887 | 1.1729 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 167 | uM | 7495.074 | 0.0023 | -0.9887 | 1.1729 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.000427 | uM | 7496.074 | 0.9780 | 0.9674 | 1.3504 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.000427 | uM | 7496.074 | 0.9780 | 0.9674 | 1.3504 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.00213 | uM | 7496.074 | 0.9067 | 0.8601 | 1.3504 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.00213 | uM | 7496.074 | 0.9067 | 0.8601 | 1.3504 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.0107 | uM | 7496.074 | 0.9212 | 0.8821 | 1.3504 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.0107 | uM | 7496.074 | 0.9212 | 0.8821 | 1.3504 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.0533 | uM | 7496.074 | 0.7089 | 0.5502 | 1.3504 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.0533 | uM | 7496.074 | 0.7089 | 0.5502 | 1.3504 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.267 | uM | 7496.074 | 0.1194 | -0.5855 | 1.3504 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.267 | uM | 7496.074 | 0.1194 | -0.5855 | 1.3504 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 1.33 | uM | 7496.074 | 0.0077 | -0.9453 | 1.3504 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 1.33 | uM | 7496.074 | 0.0077 | -0.9453 | 1.3504 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 7496.074 | 0.0037 | -0.9684 | 1.3504 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 7496.074 | 0.0037 | -0.9684 | 1.3504 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 33.3 | uM | 7496.074 | 0.0070 | -0.9492 | 1.3504 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 33.3 | uM | 7496.074 | 0.0070 | -0.9492 | 1.3504 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 167 | uM | 7496.074 | 0.0066 | -0.9513 | 1.3504 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 167 | uM | 7496.074 | 0.0066 | -0.9513 | 1.3504 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.000427 | uM | 7498.074 | 1.0246 | 1.0452 | 1.0877 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.000427 | uM | 7498.074 | 1.0246 | 1.0452 | 1.0877 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.00213 | uM | 7498.074 | 0.9792 | 0.9617 | 1.0877 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.00213 | uM | 7498.074 | 0.9792 | 0.9617 | 1.0877 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.0107 | uM | 7498.074 | 0.9880 | 0.9779 | 1.0877 |